The Renin-Angiotensin System and Diabetic Nephropathy
Summary
The renin-angiotensin system (RAS) has key regulatory functions for blood pressure and fluid homeostasis. In addition, dysregulation of the system can have maladaptive effects to promote tissue injury in chronic diseases such as hypertension, heart failure, and kidney disease. These actions for the RAS to promote disease pathogenesis are especially apparent in diabetic nephropathy, the most common cause of end-stage renal disease in the United States. Evidence of a role for the RAS in diabetic nephropathy comes from studies in animal models and randomized clinical trials showing efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to slow the progression of renal disease. Widespread applications of these therapies to a range of renal diseases may have contributed to the recent reduction in the incidence rates for end-stage renal disease. We provide a general review of the RAS and its role in diabetic nephropathy.
Keywords: Renin-angiotensin system, angiotensin II, ACE inhibitor, angiotensin receptor blocker
To access this article, please choose from the options below
Supported in part by grants from the National Institutes of Health (5 U01 HL070523-05), the American Heart Association, and the US Department of Veterans Affairs.
PII: S0270-9295(07)00010-1
doi:10.1016/j.semnephrol.2007.01.009
© 2007 Elsevier Inc. All rights reserved.
